Background
Methods
Study population
Ethical statement
Study design
Outcomes
Statistical methods and sample size
Results
Placebo group (n = 30) | Probiotic group (n = 30) |
P
1
| |
---|---|---|---|
Age (year) | 61.8 ± 9.8 | 60.7 ± 9.4 | 0.64 |
Familial history (%) | 10 (33.7) | 11 (36.7) | 0.78† |
Height (cm) | 163.2 ± 7.1 | 162.5 ± 7.2 | 0.72 |
Weight at study baseline (kg) | 78.2 ± 11.8 | 80.2 ± 15.3 | 0.57 |
Weight at end-of-trial (kg) | 78.2 ± 12.0 | 80.2 ± 15.3 | 0.56 |
Weight change (kg) | − 0.03 ± 1.1 | 0.04 ± 1.0 | 0.78 |
BMI at study baseline (kg/m2) | 29.3 ± 4.1 | 30.3 ± 5.2 | 0.42 |
BMI at end-of-trial (kg/m2) | 29.3 ± 4.1 | 30.3 ± 5.2 | 0.41 |
BMI change (kg/m2) | − 0.01 ± 0.4 | 0.06 ± 0.4 | 0.81 |
Smoking (%) | 3 (10.0) | 3 (10.0) | 1.00† |
Aspirin 80 mg (%) | 30 (100) | 30 (100) | 1.00† |
Statin (%) | 30 (100) | 30 (100) | 1.00† |
Insulin therapy (%) | 8 (26.7) | 7 (23.3) | 0.76† |
Antidiabetic drugs (%) | |||
Monotherpy | 16 (72.7) | 17 (70.8) | |
Combination therapy | 6 (27.3) | 7 (29.2) | 0.88† |
Hypertension (%) | 22 (73.3) | 23 (76.7) | 0.76† |
ACEI/ARB drugs (%) | 30 (100) | 30 (100) | 1.00† |
Blocker drugs (%) | |||
β-blocker | 28 (93.3) | 29 (96.7) | |
Calcium channel blocker | 2 (6.7) | 1 (3.3) | 0.55† |
Duration of DM (year) | 6.8 ± 2.2 | 6.6 ± 1.9 | 0.61 |
Duration of CHD (year) | 9.5 ± 2.2 | 9.3 ± 1.6 | 0.78 |
Placebo group (n = 30) | Probiotic group (n = 30) |
P
1
| |
---|---|---|---|
Energy (kcal/day) | 2182 ± 215 | 2194 ± 224 | 0.83 |
Carbohydrates (g/day) | 292.1 ± 38.1 | 298.5 ± 43.5 | 0.54 |
Protein (g/day) | 82.5 ± 23.5 | 81.5 ± 17.8 | 0.85 |
Fat (g/day) | 79.8 ± 14.6 | 79.0 ± 13.1 | 0.80 |
SFA (g/day) | 26.1 ± 5.9 | 25.9 ± 5.5 | 0.92 |
MUFA (g/day) | 22.7 ± 6.3 | 22.1 ± 5.7 | 0.69 |
PUFA (g/day) | 23.4 ± 4.3 | 22.7 ± 4.3 | 0.50 |
Cholesterol (mg/day) | 219.5 ± 128.9 | 205.1 ± 100.6 | 0.63 |
TDF (g/day) | 19.1 ± 3.8 | 19.5 ± 4.1 | 0.69 |
Variables | Placebo group (n = 30) | Probiotic group (n = 30) | Difference in outcome measures between probiotic and placebo treatment groupsa | |||
---|---|---|---|---|---|---|
Baseline | Week 12 | Baseline | Week 12 | β (95% CI) |
P
2
| |
FPG (mg/dL) | 128.8 ± 47.2 | 138.2 ± 33.5 | 133.8 ± 43.6 | 120.6 ± 38.7 | − 20.02 (− 33.86, 6.17) | 0.005 |
Insulin (μIU/mL) | 13.8 ± 8.6 | 14.7 ± 8.5 | 14.3 ± 5.6 | 13.1 ± 5.2 | − 2.09 (− 3.77, − 0.41) | 0.01 |
HOMA-IR | 4.5 ± 3.6 | 4.6 ± 3.2 | 4.8 ± 2.7 | 4.4 ± 2.4 | − 0.50 (− 0.96, − 0.03) | 0.03 |
QUICKI | 0.32 ± 0.03 | 0.31 ± 0.02 | 0.31 ± 0.02 | 0.31 ± 0.02 | 0.008 (0.001, 0.01) | 0.02 |
Triglycerides (mg/dL) | 146.2 ± 67.4 | 152.4 ± 66.9 | 139.0 ± 61.3 | 140.2 ± 64.9 | − 8.93 (− 30.54, 12.68) | 0.41 |
VLDL-cholesterol (mg/dL) | 29.2 ± 13.5 | 30.5 ± 13.4 | 27.8 ± 12.3 | 28.1 ± 13.0 | − 1.78 (− 6.10, 2.53) | 0.41 |
Total cholesterol (mg/dL) | 143.5 ± 30.5 | 146.3 ± 34.0 | 149.7 ± 26.6 | 144.6 ± 27.2 | − 6.62 (− 18.86, 5.62) | 0.28 |
LDL-cholesterol (mg/dL) | 71.2 ± 26.3 | 73.0 ± 24.1 | 74.9 ± 22.0 | 68.1 ± 21.1 | − 6.68 (− 15.53, 2.15) | 0.13 |
HDL-cholesterol (mg/dL) | 43.0 ± 7.2 | 42.8 ± 6.2 | 46.8 ± 6.7 | 48.4 ± 7.4 | 2.52 (0.04, 5.00) | 0.04 |
Total-/HDL-cholesterol ratio | 3.4 ± 0.8 | 3.4 ± 0.7 | 3.2 ± 0.6 | 3.0 ± 0.6 | − 0.27 (− 0.52, − 0.03) | 0.02 |
hs-CRP (mg/L) | 4.8 ± 2.5 | 4.9 ± 2.6 | 5.1 ± 2.8 | 4.3 ± 2.6 | − 0.88 (− 1.39, − 0.38) | 0.001 |
NO (µmol/L) | 46.6 ± 10.0 | 44.2 ± 8.3 | 42.4 ± 6.2 | 46.5 ± 7.4 | 4.28 (0.66, 7.91) | 0.02 |
TAC (mmol/L) | 895.3 ± 301.9 | 873.3 ± 276.3 | 965.5 ± 239.4 | 1044.4 ± 254.9 | 108.44 (47.61, 169.27) | 0.001 |
GSH (µmol/L) | 506.3 ± 96.5 | 505.3 ± 107.9 | 586.2 ± 156.3 | 629.4 ± 169.5 | 45.15 (5.82, 84.47) | 0.02 |
MDA (µmol/L) | 2.7 ± 0.7 | 2.6 ± 0.4 | 3.1 ± 1.3 | 2.7 ± 1.4 | − 0.23 (− 0.53, − 0.07) | 0.13 |
SBP (mmHg) | 128.3 ± 14.4 | 127.0 ± 15.1 | 125.1 ± 12.8 | 123.2 ± 13.3 | − 1.30 (− 5.96, 3.35) | 0.57 |
DBP (mmHg) | 79.3 ± 8.8 | 78.2 ± 8.5 | 77.9 ± 6.9 | 76.2 ± 8.0 | − 1.08 (− 3.51, 1.35) | 0.37 |